Allied Biotech Corporation

Informe acción TPEX:1780

Capitalización de mercado: NT$1.7b

Allied Biotech Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Allied Biotech has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 3.7% per year. Allied Biotech's return on equity is 9.1%, and it has net margins of 13.8%.

Información clave

5.6%

Tasa de crecimiento de los beneficios

5.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 12.2%
Tasa de crecimiento de los ingresos3.7%
Rentabilidad financiera9.1%
Margen neto13.8%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

Apr 16
Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Mar 05
These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Jan 24
Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

Jan 03
Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Dec 13
A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Is Allied Biotech (GTSM:1780) A Risky Investment?

Nov 25
Is Allied Biotech (GTSM:1780) A Risky Investment?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Allied Biotech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

TPEX:1780 Ingresos, gastos y beneficios (TWD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 2476910613626
31 Mar 2474510213426
31 Dec 237209713226
30 Sep 2372812113726
30 Jun 2373614414226
31 Mar 2372714514525
31 Dec 2271714714725
30 Sep 2269910513925
30 Jun 226816213125
31 Mar 226793812626
31 Dec 216771312126
30 Sep 216583211725
30 Jun 216395111425
31 Mar 216296511425
31 Dec 206187911425
30 Sep 206137211324
30 Jun 206086511224
31 Mar 206248611324
31 Dec 1963910711424
30 Sep 1967012012024
30 Jun 1970013412724
31 Mar 1972813813324
31 Dec 1876513313125
30 Sep 1876412412727
30 Jun 1876311412429
31 Mar 187159911530
31 Dec 176827111428
30 Sep 176455312726
30 Jun 176093513923
31 Mar 176032913523
31 Dec 165744013323
30 Sep 165635412024
30 Jun 165526810725
31 Mar 165385711226
31 Dec 155244611628
30 Sep 155163011828
30 Jun 155091312128
31 Mar 154921012227
31 Dec 14474712426
30 Sep 144881112326
30 Jun 145021512125
31 Mar 144911111825
31 Dec 13480611524

Ingresos de calidad: 1780 has high quality earnings.

Margen de beneficios creciente: 1780's current net profit margins (13.8%) are lower than last year (19.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 1780's earnings have grown by 5.6% per year over the past 5 years.

Acelerando crecimiento: 1780's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Beneficios vs. Industria: 1780 had negative earnings growth (-26.4%) over the past year, making it difficult to compare to the Biotechs industry average (33.2%).

Rentabilidad financiera

Alta ROE: 1780's Return on Equity (9.1%) is considered low.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

7D

1Y

7D

1Y

7D

1Y